Gut microbiota composition is associated with the efficacy of Delta-24-RGDOX in malignant gliomas
Glioblastoma, the most common primary brain tumor, has a 6.8% survival rate 5 years post diagnosis. Our team developed an oncolytic adenovirus with an OX-40L expression cassette named Delta-24-RGDOX. While studies have revealed the interaction between the gut microbiota and immunotherapy agents, no studies link the gut microbiota with viroimmunotherapy efficacy in glioblastoma.